Our study confirms the prognostic meaning of COX2 in patients with primary MM and adds a new late-stage histolpathological marker, PPARG, which may be predictive for responsiveness to biomodulatory therapy in advanced metastatic MM. This evidence concerns the gene PPARG and Miyoshi myopathy.